Work

Multi-modality assessment and prognostication of high-risk coronary plaque

Year: 2026
Type: dissertation
Study design: Observational Study
Abstract: BACKGROUND: A large proportion of patients who suffer an acute thrombotic cardiovascular event exhibit no prior clinical signs of underlying atherosclerosis. This asymptomatic progression poses a considerable diagnostic challenge and contributes substantially to global cardiovascular morbidity and mortality. Plaque rupture remains the predominant initiating mechanism for acute coronary syndromes, responsible for 60–70% of cases and typically occurs suddenly and without antecedent symptoms. Consequently, the detection and characterisation of high-risk or "vulnerable" plaques has become a central focus in advancing the understanding of atherogenesis and refining preventive strategies. Identifying- disease activity at an early stage and intervening before an acute event arises may help reduce the overall burden of atherosclerotic complications. This thesis investigates advanced imaging techniques to quantify coronary atherosclerotic burden, activity, and progression, with a focus on: • The role of lipoprotein(a) in driving adverse plaque progression and associated thrombotic risk. • The potential of 18F-sodium fluoride uptake to predict long--term- coronary events. METHODS AND RESULTS: Lipoprotein(a) and plaque progression We assessed whether elevated lipoprotein (a) (Lp(a)) drives adverse coronary plaque progression in patients with advanced stable coronary artery disease using coronary CT angiography at baseline and 12 months. High Lp(a) was defined as ≥70 mg/dL. Among 191 patients, baseline plaque burden was similar across groups, but those with high Lp(a) demonstrated greater progression of low--attenuation (necrotic core) plaque (26.2 ± 88.4 mm3 vs −0.7 ± 50.1 mm3; P = 0.020). Multivariable linear regression analysis confirmed the relation between Lp(a) and low-attenuation plaque volume progression (β = 10.5% increase for each 50 mg/dL Lp(a), 95% CI: 0.7%-20.3%). No differences were observed in total, calcific, or non-calcific plaque progression. Temporal changes in coronary 18F-fluoride uptake Coronary 18F-fluoride uptake reflects atherosclerotic disease activity and progression, but its short---term variability is unknown. This study evaluated how coronary 18F--fluoride uptake changes over 12 months in patients with either advanced chronic coronary artery disease or a recent myocardial infarction. Patients underwent serial 18F--fluoride PET–CT imaging at 3, 6, or 12 months, with uptake quantified using coronary microcalcification activity (CMA) and calcification assessed by calcium score, mass, and volume. Among 111 patients, those with chronic disease had higher baseline CMA values- reflecting the greater burden of coronary artery disease. Coronary 18F-fluoride uptake (CMA > 0) was associated with higher baseline calcium scores (294 [116-483] versus 72 [8 -222] AU; P<0.001), and more rapid progression of coronary calcification scores (39 [10-82] versus 12 [1-36] AU/year; P<0.001), compared to the absence of uptake (CMA = 0). However, Coronary 18F-fluoride uptake itself remained largely unchanged over 3, 6, and 12 months in both chronic and post-myocardial infarction groups. Coronary plaque activity and future coronary events Recurrent coronary events are common following acute myocardial infarction but are challenging to predict. We conducted a multi-centre prospective study to evaluate whether coronary atherosclerotic plaque activity, measured using 18F-sodium fluoride PET uptake, predicts longterm outcomes in 704 patients with multivessel coronary artery disease following a recent myocardial infarction. Over a median 4--year follow--up-, 141 patients experienced the composite endpoint of cardiac death (9), non-fatal myocardial (49) infarction, or unplanned revascularization (83). Increased coronary plaque activity had no demonstrable association with the primary endpoint (hazard ratio (HR) 1.25 [95% confidence interval 0.89 to 1.76], P=0.20) or unscheduled coronary revascularization (HR 0.98 [0.64 to 1.49], P=0.91) but was associated with increased risk of cardiac death or non-fatal myocardial infarction (47 versus 19; HR 1.82 [1.07 to 3.10], P=0.028) and all-cause mortality (30 versus 9; HR 2.43 [1.15 to 5.12], P=0.020). CONCLUSION: At vessel level, 18F-sodium fluoride PET is associated with atheroma progression as well as the future risk of cardiac death or myocardial infarction. As patient level, elevated Lp(a) drives accelerated progression of low-attenuation (necrotic core) plaque in advanced coronary artery disease, offering a mechanistic explanation for its association with residual myocardial infarction risk and supporting Lp(a) as a therapeutic target. Collectively, these findings highlight the importance of integrating biological and imaging biomarkers to improve risk stratification and to monitor disease progression, including response to targeted therapies.
Source: ERA
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7221793478
Cites: 197
Cited by:
Related to: 10